Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BRKR
BRKR logo

BRKR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
57.446
Open
55.360
VWAP
56.32
Vol
1.98M
Mkt Cap
8.87B
Low
54.270
Amount
111.48M
EV/EBITDA(TTM)
21.69
Total Shares
154.99M
EV
10.30B
EV/OCF(TTM)
73.28
P/S(TTM)
2.52
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.
Show More

Events Timeline

(ET)
2026-06-12
16:30:00
Bruker Files Automatic Mixed Securities Shelf
select
2026-06-04 (ET)
2026-06-04
07:20:00
Bruker Corporation Showcases New Microbial Diagnostics Solutions at ASM 2026
select
2026-06-01 (ET)
2026-06-01
07:10:00
Bruker Corporation Launches timsMRMS System
select
2026-05-26 (ET)
2026-05-26
07:10:00
Bruker Corporation Commissions Novel 18 Tesla MRI in Portugal
select

News

NASDAQ.COM
9.5
06-19NASDAQ.COM
Bruker Corporation Shares Surge 50.3% Amid Strong Growth
  • Outstanding Stock Performance: Bruker Corporation's shares have surged 50.3% over the past year, significantly outperforming the industry growth of 42.5%, reflecting the company's strong performance in life sciences and materials research, which boosts investor confidence.
  • Growth Drivers: The BSI NANO segment reported organic bookings growth exceeding expectations, driving performance in Q1 2026, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating robust market demand.
  • Financial Health: As of Q1 2026, the company reported cash and cash equivalents of $133.4 million, down from $298.8 million at the end of 2025, but reduced long-term debt by $181.3 million, lowering net leverage to 2.9X, demonstrating financial stability.
  • Competitive Challenges: While the company has gained market share in the preclinical imaging space, it faces pressure from larger competitors, particularly in a softer demand environment for academic and industrial customers, which may impact future growth potential.
Newsfilter
8.5
06-04Newsfilter
Bruker Showcases Innovations at ASM Microbe 2026
  • Portfolio Expansion: At ASM Microbe 2026, Bruker showcased innovations in microbial identification and sepsis diagnostics, particularly the MALDI Biotyper®CA system's expanded clinical capabilities, which support the identification of 549 clinically validated microbial species, significantly enhancing laboratory efficiency and diagnostic turnaround times.
  • Rapid Diagnostic Technology: The newly developed rapid antimicrobial susceptibility testing (AST) workflow, in conjunction with the MALDI Biotyper®CA system, aims to provide faster actionable diagnostics for critically ill patients, expected to accelerate clinical decision-making and improve patient outcomes.
  • Strong Market Demand: Bruker achieved 140 new system placements in 2025, with double-digit growth in consumables sales, reflecting robust demand for its MALDI Biotyper and IR Biotyper solutions in the U.S. market, with this growth momentum anticipated to continue into 2026.
  • Introduction of New Technologies: The launch of the MBioSEQ®Ridom Typer software supports reflex NGS testing as an extension of microbial identification and outbreak analysis workflows, further enhancing laboratories' epidemiological insight capabilities, marking Bruker's ongoing innovation in microbial and molecular diagnostics.
Newsfilter
3.5
06-02Newsfilter
Bruker Launches New timsMRMS System for Energy Research
  • Technological Innovation: Bruker's new timsMRMS system integrates Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), achieving over 10 million mass resolution and sub-parts-per-million mass accuracy, thereby providing unprecedented capabilities for analyzing complex fossil fuels and green energy materials.
  • Battery Research Breakthrough: The system enables ultra-high-confidence molecular characterization of electrolyte formulations, solid-electrolyte interphase (SEI) degradation, and molecular changes during charge-discharge cycles of lithium-ion batteries, assisting materials scientists in understanding and controlling the chemical mechanisms that dictate battery lifespan, safety, and energy density.
  • Sustainable Fuel Development: The timsMRMS system offers ultra-high-resolution clarity into molecular formulae determination and compound classes, streamlining the development of sustainable, low-carbon transportation fuels while addressing the challenges posed by chemical diversity in pyrolysis and biomass-derived oils.
  • Market Demand Response: As the global transition to renewable energy accelerates, the launch of the timsMRMS system not only meets the urgent need for new analytical capabilities in energy technology but also significantly enhances Bruker's competitive position in the energy research market.
seekingalpha
9.5
05-07seekingalpha
Bruker Q1 2026 Earnings Call Insights Highlight Strong Performance
  • Performance Exceeds Expectations: Bruker's Q1 2026 reported revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic revenue decline, indicating the company's resilience in challenging conditions.
  • AI-Driven Growth: The company achieved over 20% organic bookings growth in its AI-driven semiconductor metrology, SciY scientific software, and lab digitization businesses, suggesting strong market demand in these areas that could drive overall revenue recovery.
  • Order Momentum: The BEST segment secured approximately $80 million in multi-year orders in Q1, while superconductors orders reached about $600 million over the last five months, demonstrating the company's ability to recover in key technology sectors.
  • 2026 Outlook: Management reaffirmed the 2026 revenue guidance of $3.57 billion to $3.60 billion, expecting organic revenue growth of 1% to 2%, with a forecast for low to mid-single-digit organic revenue growth in Q2, reflecting cautious optimism about future market conditions.
seekingalpha
9.5
05-06seekingalpha
Bruker Q1 Earnings Exceed Expectations with Strong Guidance
  • Earnings Beat: Bruker's Q1 non-GAAP EPS of $0.31 surpassed expectations by $0.08, indicating a robust profitability trend that enhances investor confidence in the company's financial health.
  • Revenue Growth: The company reported Q1 revenue of $823.4 million, reflecting a 2.7% year-over-year increase and exceeding market expectations by $27.73 million, showcasing its competitive strength and sales capabilities.
  • Strong Bookings: Bruker Scientific Instruments saw high-single-digit organic growth in bookings year-over-year, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating strong market demand and a positive business outlook.
  • Guidance Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, projecting a 4% to 5% year-over-year increase, with non-GAAP EPS expectations of $2.10 to $2.15, reflecting confidence in future performance.
Newsfilter
9.5
05-06Newsfilter
Bruker Exceeds Expectations in Q1 Financial Results
  • Revenue Growth: Bruker's Q1 2026 revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic decline, demonstrating resilience amid market challenges.
  • Profitability Decline: The GAAP diluted EPS for Q1 was $0.02, a significant drop from $0.11 in Q1 2025, highlighting the impact of cost pressures and market conditions on profitability.
  • Strong Orders: The Bruker Scientific Instruments segment saw high single-digit percentage growth in bookings year-over-year, with a book-to-bill ratio exceeding 1.0 for the third consecutive quarter, indicating robust market demand, particularly in semiconductor and industrial research sectors.
  • Financial Outlook Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, representing a 4% to 5% year-over-year increase, with non-GAAP EPS expected to grow by 15% to 17%, reflecting confidence in future growth.
Wall Street analysts forecast BRKR stock price to rise
12 Analyst Rating
Wall Street analysts forecast BRKR stock price to rise
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
40.00
Averages
52.18
High
60.00
Current: 0.000
sliders
Low
40.00
Averages
52.18
High
60.00
BofA
Buy
maintain
$49 -> $65
AI Analysis
2026-06-02
Reason
BofA
Price Target
$49 -> $65
AI Analysis
2026-06-02
maintain
Buy
Reason
BofA raised the firm's price target on Bruker to $65 from $49 and keeps a Buy rating on the shares. Diagnostic tools have rallied almost 10% in the last few days, but valuations are "still not excessive / overly elevated," says the analyst, who raised target for a trio of names in the group to reflect improved sentiment.
Wolfe Research
analyst
Outperform
to
Peer Perform
downgrade
$NULL
2026-06-01
Reason
Wolfe Research
analyst
Price Target
$NULL
2026-06-01
downgrade
Outperform
to
Peer Perform
Reason
As previously reported, Wolfe Research downgraded Bruker to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock. Bruker \"has gotten really expensive versus the group really quickly,\" says the analyst, who adds that the environment \"needs to cooperate\" and be less bad to achieve current estimates
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BRKR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 15.22, compared to its 5-year average forward P/E of 25.16. For a more detailed relative valuation and DCF analysis to assess Bruker Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.16
Current PE
15.22
Overvalued PE
32.05
Undervalued PE
18.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.87
Current EV/EBITDA
22.32
Overvalued EV/EBITDA
21.79
Undervalued EV/EBITDA
13.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.08
Current PS
2.33
Overvalued PS
4.13
Undervalued PS
2.03

Financials

AI Analysis
Annual
Quarterly

Whales Holding BRKR

N
Needham Investment Management, LLC
Holding
BRKR
+67.84%
3M Return
P
Pallas Capital Advisors LLC
Holding
BRKR
+32.77%
3M Return
V
Vaughan Nelson Investment Management, L.P.
Holding
BRKR
+19.85%
3M Return
S
Samlyn Capital, LLC
Holding
BRKR
+12.72%
3M Return
O
Orbis Investment Management Limited
Holding
BRKR
+11.63%
3M Return
S
Sculptor Capital Management, Inc.
Holding
BRKR
+10.65%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 57.23 USD — it has increased 4.57

What is Bruker Corp (BRKR)'s business?

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.

What is the price predicton of BRKR Stock?

Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Bruker Corp (BRKR)'s revenue for the last quarter?

Bruker Corp revenue for the last quarter amounts to 823.40M USD, increased 2.75

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

Bruker Corp. EPS for the last quarter amounts to 0.02 USD, decreased -81.82

How many employees does Bruker Corp (BRKR). have?

Bruker Corp (BRKR) has 11085 emplpoyees as of June 20 2026.

What is Bruker Corp (BRKR) market cap?

Today BRKR has the market capitalization of 8.87B USD.